By Kelly Simpson, Manager, Global Initiatives
A special introductory workshop on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Chronic Myelogenous Leukemia (CML) was held for an intimate group of prestigious Chinese thought leaders on December 6, 2010 in Orlando, Florida. To facilitate the discussion, Jerald P. Radich, MD, of Fred Hutchinson Cancer Research Center gave a brief presentation on State-of-the-Art CML Management: The Role of NCCN Guidelines™ and the Future of CML Treatment. The group then discussed CML care and outcomes in China, as presented by Prof. Wang Jianxiang of the Leukemia Center, Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College.
On December 8th, NCCN hosted the group of Chinese CML experts as part of a Global Leadership Exchange Program. In Fort Washington, Pennsylvania, William T. McGivney, PhD, Chief Executive Officer, NCCN, partnered with Eva Lepisto, MSc, Vice President, Technology Research & Development, NCCN, and Joan S. McClure, MS, Senior Vice President, Clinical Information & Publications, NCCN, to inform the visiting delegation on matters such as the policy environment in the United States and about a number of NCCN initiatives such as the NCCN Non-Hodgkin’s Lymphomas (NHL) Outcomes Database, NCCN CML Guidelines User System, and NCCN Informatics Collaborations. Prof. Jianmin Wang, from the Department of Hematology at The Second Military Medical University Shanghai Changhai Hospital, educated NCCN participants on CML in China and initiated an insightful discussion that continued through lunch.
On the second day of the Global Leadership Exchange, the group toured Memorial Sloan-Kettering Cancer Center (MSKCC) in New York, New York. Senior Vice President Thomas J. Fahey, Jr., MD, coordinated and hosted a substantial program for the visiting CML clinicians. Martin S. Tallman, MD, Chief, Leukemia Service, spoke on the MSKCC Leukemia Service and its relationship to other services within the division of Hematology/Oncology and about organizing multicenter clinical trials. Diagnosis and treatment of hematologic malignancies were discussed by Peter Maslak, MD, Chief, Hematology Laboratory Service, and Joseph G. Jurcic, MD, Attending Physician, Leukemia Service, talked about key clinical trials at MSKCC for hematologic malignancies. Ellin Berman, MD, Attending Physician, Leukemia Service, and Ross Levine, MD, Geoffrey Beene Junior Faculty Chair, presented on new treatment insights, including new therapeutic targets in CML and other myeloproliferative neoplasms. Dr. Fahey closed the day with a brief presentation on current programs and activities at MSKCC and some background on its history. The group, led by Dr. Fahey, lastly toured various areas of MSKCC and interacted with a number of department representatives along the way.The goal of all NCCN initiatives is to improve care for patients with cancer. Both the CML Workshop, as well as the Global Leadership Exchange for CML Clinicians, served as significant opportunities for open dialogue on the vast knowledge and expertise of the participating American and Chinese practitioners. Dr. Radich, NCCN, and the Chinese CML assembly anticipate a subsequent meeting during which work will begin on the development of NCCN Guidelines on Chronic Myelogenous Leukemia: China Edition.